[Immunotherapy for lung cancer]

Area of Science:

• Oncology
• Immunotherapy

Background:

• Lung cancer is strongly linked to tobacco smoking, resulting in high mutation rates and immunogenicity.
• Immune checkpoint inhibitors represent a significant advancement in treating various malignancies, including lung cancer.

Purpose of the Study:

• To review the role and efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).
• To highlight the impact of PD-1 and PD-L1 inhibitors in different treatment settings.

Main Methods:

• Review of clinical trial data, including the KEYNOTE-024 trial.
• Analysis of approved and investigational immune checkpoint inhibitors for NSCLC.

Main Results:

• Nivolumab, pembrolizumab (PD-1 inhibitors), and atezolizumab (PD-L1 inhibitor) are approved for second-line advanced NSCLC.
• Pembrolizumab demonstrated doubled progression-free survival and improved overall survival in PD-L1 expressing NSCLC, establishing it as a first-line standard.
• Avelumab and durvalumab show promising activity.

Conclusions:

• Immune checkpoint inhibitors, particularly pembrolizumab, have transformed first-line treatment for advanced NSCLC with high PD-L1 expression.
• Ongoing trials are exploring combinations of immune checkpoint inhibitors with chemotherapy, targeted agents, and adjuvant therapies in lung cancer.